Jefferies Financial Group Inc. Buys New Position in Azenta, Inc. $AZTA

Jefferies Financial Group Inc. bought a new position in Azenta, Inc. (NASDAQ:AZTA – Free Report) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 48,450 shares of the company’s stock, valued at approximately $1,690,000.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Legal & General Group Plc bought a new position in Azenta during the 2nd quarter valued at $2,453,000. Hsbc Holdings PLC bought a new position in Azenta during the second quarter valued at about $1,108,000. Jupiter Topco LLC bought a new position in Azenta during the second quarter valued at about $435,000. Meros Investment Management LP bought a new position in Azenta during the second quarter valued at about $5,625,399. Finally, Man Group plc acquired a new position in Azenta during the second quarter worth about $9,402,000. 99.08% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Azenta

Investors following AZTA have been watching these headlines:

  • Positive Sentiment: Coverage highlighted commercial execution and new gene-synthesis capabilities as factors supporting Azenta’s outlook. KeyCorp’s estimates call for $0.69 EPS in FY2027 and $0.84 in FY2028; these are analyst forecasts, not company guidance. Article: Azenta Q3 Deep Dive
  • Neutral Sentiment: After the sharp post-earnings advance, some investors took profits, contributing to a pullback; this may reflect near-term trading rather than a change in the company’s fundamentals. Article: Azenta Dips as Investors Book Profits
  • Negative Sentiment: Rosen Law Firm said it is investigating potential securities claims tied to allegations that Azenta may have issued materially misleading business information. The investigation is an allegation, not a finding of wrongdoing, but may weigh on sentiment. Article: Rosen Law Firm Investor Notice

Wall Street Analyst Weigh In

Several brokerages have commented on AZTA. Weiss Ratings upgraded shares of Azenta from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, August 26th. Wall Street Zen raised shares of Azenta from a “hold” rating to a “buy” rating in a report on Saturday. Zacks Research began coverage on shares of Azenta in a research report on Thursday. They set a “hold” rating for the company. Needham & Company LLC lifted their price objective on shares of Azenta from $37.00 to $57.00 and gave the stock a “buy” rating in a research note on Wednesday, November 11th. Finally, Jefferies Financial Group lifted their price objective on shares of Azenta from $44.00 to $52.00 and gave the stock a “buy” rating in a research note on Wednesday, November 11th. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Azenta presently has a consensus rating of “Hold” and a consensus target price of $47.60.

View Our Latest Report on AZTA

Azenta Stock Performance

Shares of NASDAQ:AZTA opened at $45.65 on Monday. Azenta, Inc. has a one year low of $15.93 and a one year high of $50.06. The stock has a fifty day moving average of $36.52 and a 200-day moving average of $28.56. The company has a market capitalization of $2.00 billion, a PE ratio of -12.61 and a beta of 1.47.

Azenta (NASDAQ:AZTA – Get Free Report) last released its quarterly earnings data on Tuesday, November 10th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.17. The business had revenue of $167.09 million during the quarter, compared to analyst estimates of $160.16 million. Azenta had a positive return on equity of 1.41% and a negative net margin of 26.86%. As a group, research analysts forecast that Azenta, Inc. will post 0.69 EPS for the current fiscal year.

About Azenta

(Free Report)

Azenta, Inc. provides products and services for life sciences research and the management of biological samples. Its offerings include automated sample storage systems, laboratory automation equipment, consumables, and software used to track and manage samples. The company also provides genomic services through GENEWIZ, including sequencing and other genetic analysis services for researchers and organizations in the life sciences and pharmaceutical industries. Azenta was formed in 2021 when Brooks Automation separated its life sciences business and adopted the Azenta name.

Further Reading

Want to see what other hedge funds are holding AZTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Azenta, Inc. (NASDAQ:AZTA – Free Report).

Institutional Ownership by Quarter for Azenta (NASDAQ:AZTA)

Receive News & Ratings for Azenta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azenta and related companies with MarketBeat.com's FREE daily email newsletter.